KORY J. LAVINE

Dr. KORY J. LAVINE

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Nature
Verified
Journal Article
Closed access
PDF file
CKChristoph Kuppe
Christoph Kuppe
RFRicardo O. Ramirez Flores
Ricardo O. Ramirez Flores
ZLZhijian Li
Zhijian Li
SHSikander Hayat
Sikander Hayat
RLRebecca T. Levinson
Rebecca T. Levinson
RKRafael Kramann
Rafael Kramann

11 June 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GBGeetika Bajpai
Geetika Bajpai
CSCaralin Schneider
Caralin Schneider
NWNicole Wong
Nicole Wong
ABAndrea Bredemeyer
Andrea Bredemeyer
MHMaarten Hulsmans
Maarten Hulsmans
KLKORY J. LAVINE
KORY J. LAVINE

16 March 2022 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
AKAndrew L. Koenig
Andrew L. Koenig
ISIrina Shchukina
Irina Shchukina
JAJunedh Amrute
Junedh Amrute
PAPrabhakar S. Andhey
Prabhakar S. Andhey
KZKonstantin Zaitsev
Konstantin Zaitsev
KLKORY J. LAVINE
KORY J. LAVINE
Heart failure represents a major cause of morbidity and mortality worldwide. Single-cell transcriptomics have revolutionized our understanding of cell composition and associated gene expression. Through integrated analysis of single-cell and single-nucleus RNA-sequencing data generated from 27 healthy donors and 18 individuals with dilated cardiomyopathy, here we define the cell composition of the healthy and failing human heart. We identify cell-specific transcriptional signatures associated with age and heart failure and reveal the emergence of disease-associated cell states. Notably, cardiomyocytes converge toward common disease-associated cell states, whereas fibroblasts and myeloid cells undergo dramatic diversification. Endothelial cells and pericytes display global transcriptional shifts without changes in cell complexity. Collectively, our findings provide a comprehensive analysis of the cellular and transcriptomic landscape of human heart failure, identify cell type-specific transcriptional programs and disease-associated cell states and establish a valuable resource for the investigation of human heart failure.

23 October 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JAJunedh M. Amrute
Junedh M. Amrute
XLXin Luo
Xin Luo
VPVinay Penna
Vinay Penna
SYSteven Yang
Steven Yang
TYTracy Yamawaki
Tracy Yamawaki
KLKORY J. LAVINE
KORY J. LAVINE

27 July 2021 in Immunity
Verified
Journal Article
Closed access
NWNicole R. Wong
Nicole R. Wong
JMJay Mohan
Jay Mohan
BKBenjamin J. Kopecky
Benjamin J. Kopecky
SGShuchi Guo
Shuchi Guo
LDLixia Du
Lixia Du
KLKORY J. LAVINE
KORY J. LAVINE

2 January 2024 in Circulation
Verified
Journal Article
Closed access
Pan MaPan Ma
Pan Ma
JLJing Liu
Jing Liu
JQJuan Qin
Juan Qin
LLLulu Lai
Lulu Lai
GHGyu Seong Heo
Gyu Seong Heo
KLKORY J. LAVINE
KORY J. LAVINE
BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte–associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages. METHODS: We used an established murine ICI myocarditis model ( Ctla4 +/– Pdcd1 –/– mice) to explore the cardiac immune landscape using single-cell RNA-sequencing, immunostaining, flow cytometry, in situ RNA hybridization, molecular imaging, and antibody neutralization studies. RESULTS: We observed marked increases in CCR2 (C-C chemokine receptor type 2) + monocyte-derived macrophages and CD8 + T-cells in this model. The macrophage compartment was heterogeneous and displayed marked enrichment in an inflammatory CCR2 + subpopulation highly expressing Cxcl9 (chemokine [C-X-C motif] ligand 9), Cxcl10 (chemokine [C-X-C motif] ligand 10), Gbp2b (interferon-induced guanylate-binding protein 2b), and Fcgr4 (Fc receptor, IgG, low affinity IV) that originated from CCR2 + monocytes. It is important that a similar macrophage population expressing CXCL9 , CXCL10 , and CD16α (human homologue of mouse FcgR4) was expanded in patients with ICI myocarditis. In silico prediction of cell-cell communication suggested interactions between T-cells and Cxcl9 + Cxcl10 + macrophages via IFN-γ (interferon gamma) and CXCR3 (CXC chemokine receptor 3) signaling pathways. Depleting CD8 + T-cells or macrophages and blockade of IFN-γ signaling blunted the expansion of Cxcl9 + Cxcl10 + macrophages in the heart and attenuated myocarditis, suggesting that this interaction was necessary for disease pathogenesis. CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ–induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.